The adage 'biotech companies are bought, not sold' means an acquisition is typically not the result of a company actively seeking a buyer. As with Portola's sale to Alexion, it is often a fiduciary responsibility to consider an unsolicited offer, even if the internal plan is independent growth.
After the 2007-2013 biotech IPO drought, Portola Pharmaceuticals successfully went public by setting reasonable expectations. The goal wasn't a sky-high valuation but to gain liquidity and access to capital, recognizing the IPO is a starting line, not a finish line, for value creation.
During market downturns, biotech companies lose the ability to raise capital simply when it's convenient. Financing becomes tied to specific events. The key is timing a fundraise immediately before or after the release of significant clinical data that de-risks the company and attracts new investors.
Investors bet against new drug launches because the shift from a research-focused culture to a commercial one is seen as an 'unnatural transition.' Companies are graded harshly on early results, creating a predictable valuation dip that hedge funds exploit, as seen with Portola Pharmaceuticals.
Madrigal defied the typical 12-18 month pre-launch hiring window by bringing in a new CEO just seven months before approval. He leveraged his network to quickly assemble an experienced commercial team he had worked with before, enabling the company to build a sales force and launch in record time.
A biotech transitioning from a small, 'fit-for-purpose' R&D team to a large commercial organization gets a rare chance to create a new culture. Madrigal treated its rapid growth from ~100 to over 500 people as an opportunity to establish fresh core values for the newly-formed enterprise.
Instead of a broad launch targeting primary care, Madrigal focused its specialty sales force on the 315,000 patients already diagnosed with moderate-to-severe MASH. This disciplined approach of targeting a specific, existing patient population allowed for efficient market penetration and rapid success.